{"id":"W4409147719","doi":"10.1038/s41408-025-01259-z","title":"Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"Cilag; Pharmacyclics; Genentech; National Institutes of Health; National Cancer Institute; University College London; National Institute for Health and Care Research; Ascentage Pharma; SkylineDx; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Celgene; Swedish Orphan Biovitrum; Array BioPharma; Kite Pharma; Gilead Sciences; BeiGene; Sanofi; Amgen; Bristol-Myers Squibb Foundation; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Progression-free survival; Dosing; Oncology; Surgery; Gastroenterology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058273,0.0002037304,0.0004173775,0.000403373,0.0002363999,0.00004263131,0.0002511448,0.00005801917,0.0001823985],"category_scores_gemma":[0.0002129329,0.0001310972,0.0002319584,0.0003291208,0.00008368563,0.000144502,0.00003047257,0.0001881651,6.802862e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006985452,"about_ca_system_score_gemma":0.0007359252,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000885081,"about_ca_topic_score_gemma":0.003239773,"domain_scores_codex":[0.9975008,0.0002305283,0.0006405111,0.000283201,0.001055668,0.0002892339],"domain_scores_gemma":[0.9977626,0.0004437215,0.0004070726,0.0004175686,0.0008319652,0.0001370905],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003311236,0.006204061,0.5895035,0.00003398539,0.003296649,0.00002870785,0.0009433347,0.0001018095,0.003220721,0.00005797795,0.00008154528,0.3932165],"study_design_scores_gemma":[0.03883728,0.004177864,0.9391941,0.0003457119,0.002611373,0.00002547057,0.001155518,0.004359676,0.006115372,0.0001140692,0.002953983,0.0001096014],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934024,0.00231296,0.0001132905,0.0002970374,0.0006704638,0.002210148,0.00005779663,0.0000158794,0.0009200007],"genre_scores_gemma":[0.9956607,0.001938519,0.000708055,0.00002131934,0.0004870058,0.0005446722,0.00003543269,0.00002401771,0.0005802874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3931069,"threshold_uncertainty_score":0.5345989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08100113878727644,"score_gpt":0.4097567351272792,"score_spread":0.3287555963400027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}